Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.

Lorscheider, Johannes; Benkert, Pascal; Lienert, Carmen; Hänni, Peter; Derfuss, Tobias; Kuhle, Jens; Kappos, Ludwig; Yaldizli, Özgür

Lorscheider, Johannes; Benkert, Pascal; Lienert, Carmen; Hänni, Peter; Derfuss, Tobias; Kuhle, Jens; Kappos, Ludwig; Yaldizli, Özgür.

Afiliación

Lorscheider J; Neurologic Clinic and Policlinic, Department of Neurology, University Hospital Basel, Basel, Switzerland.
Benkert P; Clinical Trial Unit, University Hospital Basel, Basel, Switzerland.
Lienert C; Rheinburg-Klinik, Walzenhausen, Switzerland.
Hänni P; Swiss Federation for Common Tasks of Health Insurances (SVK), Solothurn, Switzerland.
Derfuss T; Neurologic Clinic and Policlinic, Department of Neurology, University Hospital Basel, Basel, Switzerland.
Kuhle J; Neurologic Clinic and Policlinic, Department of Neurology, University Hospital Basel, Basel, Switzerland.
Kappos L; Neurologic Clinic and Policlinic, Department of Neurology, University Hospital Basel, Basel, Switzerland.
Yaldizli Ö; Neurologic Clinic and Policlinic, Department of Neurology, University Hospital Basel, Basel, Switzerland.

Mult Scler ; 24(6): 777-785, 2018 05.

Article en En | MEDLINE | ID: mdl-29685071

Asunto(s)

Clorhidrato de Fingolimod/uso terapéutico; Factores Inmunológicos/uso terapéutico; Inmunosupresores/uso terapéutico; Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico; Natalizumab/uso terapéutico; Adulto; Progresión de la Enfermedad; Femenino; Humanos; Masculino; Persona de Mediana Edad; Sistema de Registros; Resultado del Tratamiento

Palabras clave

Multiple sclerosis; disability progression; fingolimod; natalizumab; observational study; relapse rate

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Clorhidrato de Fingolimod / Natalizumab / Factores Inmunológicos / Inmunosupresores Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Suiza

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google